Pliant Therapeutics, Inc. cash flow to debt ratio of -440.94% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Pliant Therapeutics, Inc.'s free cash flow has increased -19.23% from $-159.35M last year to $-128.71M, signaling increasing performance

Pliant Therapeutics, Inc.'s debt to equity ratio is 0.17, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Pliant Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.20 last year to 0.17 today, signaling strengthened financials

Pliant Therapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Pliant Therapeutics, Inc.'s interest coverage ratio is -67.73, which means that the company struggles to meet interest obligations, signaling financial risk.

Pliant Therapeutics, Inc. has insufficient data to evaluate this check.

Pliant Therapeutics, Inc.'s short-term assets of $196.45M exceed its short-term liabilities of $16.36M

Pliant Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pliant Therapeutics, Inc.'s return on equity of -59.06%, is lower than 15.00%, indicating bad performance

Pliant Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Pliant Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Pliant Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Pliant Therapeutics, Inc. has negative free cash flow, indicating cash burn

Pliant Therapeutics, Inc.'s yearly earnings has increased -28.99% since last year from $-210.30M to $-149.34M, signaling increasing performance

Pliant Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -61.46% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pliant Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Pliant Therapeutics, Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance

Pliant Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Pliant Therapeutics, Inc. has insufficient data to evaluate this check.

Pliant Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pliant Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Pliant Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Pliant Therapeutics, Inc. has insufficient data to evaluate this check.

Pliant Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pliant Therapeutics, Inc. has a price-to-book ratio of 0.43x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Pliant Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue